Elimination of lymphatic filariasis: current perspectives on mass drug administration.

Printer-friendly version
TitleElimination of lymphatic filariasis: current perspectives on mass drug administration.
Publication TypeJournal Article
AuthorsGyapong JO, Owusu IO, da-Costa Vroom FB, Mensah EO, Gyapong M
Abbrev. JournalRRTM
JournalResearch and Reports in Tropical Medicine
Year of Publication2018
VolumeVolume 9
Publication Languageeng
KeywordsElimination, Lymphatic filariasis, Mass Drug Administration (MDA), Neglected tropical diseases (NTDs), Treatment

Following the London declaration on neglected tropical diseases (NTDs) in 2012 and inspired by the WHO 2020 roadmap to control or eliminate NTDs, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) intensified preventive chemotherapy and management of morbidity as the two main strategies to enhance progress towards the elimination of lymphatic filariasis (LF). This paper focuses on current perspectives of mass drug administration (MDA) towards the elimination of LF. The goal of MDA is to reduce the density of parasites circulating in the blood of infected persons and the intensity of infection in communities to levels where transmission is no longer sustainable by the mosquito vector. Three drugs, diethylcarbamazine, albendazole, and ivermectin are currently available for LF treatment, and their effectiveness and relative safety have opened the possibility of treating the entire population at risk. Currently, almost all LF endemic countries rely on the single-dose two-drug regimen recommended by the GPELF to achieve elimination. The 4th WHO report on NTDs has indicated that considerable progress has been made towards elimination of LF in some countries while acknowledging some challenges. In this review, we conclude that the 2020 elimination goal can be achieved if issues pertaining to the drug distribution, health system and implementation challenges are addressed.